Back to mobile site

Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel on Ph2b BROADEN2 Data

September 21, 2026 4:34 PM EDT Send to a Friend
Stifel analyst Alex Thompson raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $152.00 (from $132.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login